ZBIO vs ZYME: fair value comparison
Zenas BioPharma, Inc. Common Stock and Zymeworks Inc. · Updated 2026-10-19
ZBIO has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. ZYME's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. Within Healthcare, ZBIO currently ranks higher by quality score.
| ZBIO | ZYME | |
|---|---|---|
| Verdict | No estimate yet | Awaiting full valuation |
| Last price | $24.84 | $25.03 |
| 12-month range | $15.20–$43.17 | $16.46–$31.05 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #278 of 301 Healthcare | #279 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | High | High |
| Margin trend | — | Contracting |
| Revenue growth | Declining | Declining |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The lower-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: ZBIO fair value analysis · ZYME fair value analysis